Sales of Trimeris’ HIV drug reverse downward slide in second quarter
DURHAM, N.C. – Sales of the HIV drug Fuzeon ended a six-month slide in the second quarter, biopharmaceutical firm Trimeris reported Thursday.
Trimeris (Nasdaq: TRMS) sells the drug internationally in partnership with Roche.
Fuzeon sales increased 5 percent from the first quarter to $29.1 million in the second three months of 2009. However, that total still represents a 24 percent drop from $38.3 million in the same quarter of 2008.
Global sales increased 9 percent from the first quarter to $19.4 million, but U.S. and Canada sales fell 2 percent to $9.7 million from $10 million in the first quarter and 39 percent from a year ago.
Sales in the U.S. and Canada are less than a third of the $32.9 million reported in the second quarter of 2007.
Trimeris will announce its overall financial results in August.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
The Skinny
- Groundwork Labs refocuses mission as Triangle Startup Factory nears launch
- Epic Games' Tim Sweeney reaps arts Hall of Fame honor today
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says